Bangladesh Recipe Approval and the Quarterly DGDA Committee Cycle

1. Key takeaways

The Recipe Approval step of Bangladesh registration — the first step of the two-step process — is not reviewed on a rolling basis. Applications are considered at the quarterly meetings of DGDA (practical estimate: once per quarter). This changes the smallest scheduling unit of a Bangladesh project from the week to the quarter: missing one meeting cycle means waiting roughly three additional months. It is also one of the organisational reasons behind the gap between the official timeline of 4–6 months and the practical reality of 12–24 months. Project plans written in weekly increments therefore do not survive contact with the Bangladesh calendar; the schedule must be rebuilt around the meeting dates themselves, with every preparation activity anchored to the next realistic meeting cycle rather than to a notional review duration.

• Recipe approval must be deliberated at a DGDA meeting: the primary review of step one requires a DGDA meeting, at which the committee evaluates the application and decides whether to advance it or reject it (registration practice consolidation, practical estimate).
• The meetings are held quarterly — once per quarter (practical estimate).
• Step one takes approximately 3–4 months (practical estimate).
• The organisational form of the technical judgement: the device expert committee is established by the government and operates as a technical sub-committee of the Drug Control Committee, as set out in §8 of the DGDA Medical Device Registration Guidelines.

2. Legal basis

The table below consolidates the basis for the quarterly review rhythm. The timing figures derive from registration practice, while the organisational character of the reviewing body — a technical sub-committee rather than a standing examination window — is anchored in §8 of the DGDA Medical Device Registration Guidelines. Together they explain why review progress in Bangladesh is tied to meeting cycles rather than to continuous processing capacity.

3. Expert insights

Insight one: §8 of the Guidelines provides the organisational explanation for quarterly meetings. Section 8 provides that the device expert committee is a technical sub-committee of the Drug Control Committee. A technical sub-committee is not a standing approval window; it is a deliberative body that functions through meetings. Once this organisational reality is understood, it becomes clear why review timelines in Bangladesh cannot be shortened by chasing the authorities — what you chase is a window, but what you wait for is a meeting date. Follow-up calls and reminder letters do not create additional meeting capacity; the only genuine lever is arriving at the next meeting fully prepared.

Insight two: the quarterly meeting cycle turns submission timing into a core competitive capability. Consider two manufacturers that each need three months of preparation. Company A submits one week before a meeting cycle; company B submits one week after the same cycle. The two companies may receive their certificates a full quarter apart, even though their preparation effort is identical. In Bangladesh, the choice of submission date influences the certification timeline more than the polish of the dossier does — on the premise that both matters matter. This inverts the planning instinct that most companies bring from markets with continuous review, where filing early is always the right answer. In Bangladesh, filing early merely to hit a missed cycle converts preparation time into idle queue time.

Insight three: the cost of a rejection is amplified by the quarterly cadence. In a market that operates weekly, a returned application that is corrected and resubmitted loses time measured in weeks. In Bangladesh, the same return loses time measured in quarters, because the corrected dossier must wait for the next meeting to be tabled again. This is precisely why the element self-check before step-one submission is not optional housekeeping but a cost-control instrument. Every item verified before filing removes a scenario in which three months of calendar time would be spent discovering a missing document at the meeting itself. The economics are stark: the self-check costs hours, while the failure it prevents costs a quarter of calendar time and the momentum of the entire project.

4. Practical recommendations

• Issue a meeting calendar as the first working document for every Bangladesh client: confirm the committee meeting dates for the current year with local partners at project kickoff.
• Select the two nearest meeting cycles as candidate targets, and set the dossier completion date at least 4 weeks before the target meeting to reserve time for internal review and binding.
• If the dossier cannot make the first candidate meeting, do not file as quickly as possible; instead, explicitly re-target the second meeting and use the interval to advance the embassy attestation and other step-two materials, so that the waiting period produces real output rather than idle time.
• Treat the quarterly cadence as a fixed constraint in the project schedule and communicate it to stakeholders at kickoff, so that internal expectations match the meeting-driven rhythm rather than a rolling review assumption.
• Label all meeting-cycle information as a practical estimate and plan to re-confirm the annual meeting schedule at the beginning of each year.

5. Verification checklist

• □ The committee meeting dates for the current year have been confirmed with local partners
• □ A target meeting has been selected and the dossier completion date is set at least 4 weeks before it
• □ The work to be advanced in parallel during step-one review has been identified (original CFS, physical packaging samples)
• □ The element self-check has been completed to the standard of “a return costs a full quarter”
• □ The meeting-cycle information has been marked as a practical estimate and is scheduled for annual re-confirmation

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Bangladesh. Our team prepares dossiers to DGDA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Regulatory information verified as of October 27, 2026.